<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="199989">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00486824</url>
  </required_header>
  <id_info>
    <org_study_id>97873</org_study_id>
    <nct_id>NCT00486824</nct_id>
  </id_info>
  <brief_title>Indomethacin Versus Nifedipine for Preterm Labor Tocolysis</brief_title>
  <official_title>Indocin Versus Nifedipine for Preterm Labor Tocolysis - A Randomized Double-Blinded Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Indomethacin and Nifedipine are commonly used medications for treatment of pre term labor.
      This study will compare the efficacy and adverse outcomes of oral nifedipine versus oral
      indomethacin for preterm labor tocolysis in an effort to identify which drug is most
      effective.

      Patients diagnosed with preterm labor who grant consent will be randomized by the pharmacy
      to receive oral nifedipine or oral indomethacin. Both the patient and primary medical
      provider will be blinded to the identity of the study drug. An abdominal ultrasound will be
      performed in the labor and delivery unit prior to the administration of the tocolytic in
      order to assess fetal position and fluid level, and to document fetal cardiac activity and
      movement, and will be repeated at 48 hours post-randomization. Following randomization, the
      patient will be given either 50 mg oral indomethacin with two pills of placebo, or 3 pills
      each containing 10 mg oral nifedipine for a total of 30 mg. The patients will then receive
      either 25 mg of oral indomethacin every 6 hours for 48 hours, or 20 mg of oral nifedipine
      every 6 hours for 48 hours. Tocolysis beyond 48 hours will not be used.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presenting between 24-34 weeks gestation diagnosed with preterm labor who grant
      consent will be randomized by the pharmacy to receive oral nifedipine or oral indomethacin.
      Both the patient and primary medical provider will be blinded to the identity of the study
      drug. An abdominal ultrasound will be performed in the labor and delivery unit prior to the
      administration of the tocolytic in order to assess fetal position and fluid level, and to
      document fetal cardiac activity and movement, and will be repeated at 48 hours
      post-randomization. Following randomization, the patient will be given either 50 mg oral
      indomethacin with two pills of placebo, or 3 pills each containing 10 mg oral nifedipine for
      a total of 30 mg. The patients will then receive either 25 mg of oral indomethacin every 6
      hours for 48 hours, or 20 mg of oral nifedipine every 6 hours for 48 hours. Tocolysis beyond
      48 hours will not be used. Antibiotics and steroids for fetal lung maturity will be
      administered as per standard of care for preterm labor. Maternal side effects and delivery
      outcomes will be assessed from questionnaires administered by the study team following
      treatment, and/or from review of the patient's medical records.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrent preterm labor within two weeks of randomization</measure>
    <time_frame>Two weeks after enrolled and randomized</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Birth weight, gestational age, delay of delivery, neonatal morbidities, maternal side effects, time to uterine quiescence</measure>
    <time_frame>Discharge of mother and neonate</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Obstetric Labor, Premature</condition>
  <arm_group>
    <arm_group_label>Indomethacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg. oral Indomethacin initially, followed by 25 mg every 6 hrs for 48 hrs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nifedipine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>30 mg Nifedipine initially followed by 10 mg every 6 hrs for 48 hrs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indomethacin</intervention_name>
    <description>One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.</description>
    <arm_group_label>Indomethacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine</intervention_name>
    <description>Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.</description>
    <arm_group_label>Nifedipine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton and twin gestations

          -  Intact amniotic membranes

          -  No contra-indications to tocolysis

          -  24-34 weeks gestation by last menstrual period and/or ultrasound

          -  Documented cervical change, and regular painful uterine contractions at least every 5
             minutes, or at least 2 cm cervical dilation and 80% effacement

        Exclusion Criteria:

          -  Ruptured amniotic membranes

          -  Signs/symptoms of chorioamnionitis (maternal temperature greater than 100.4 F/38.0 C,
             fetal tachycardia, uterine tenderness)

          -  Non-reassuring fetal heart rate tracings

          -  Contra-indications to indomethacin or nifedipine

          -  Contra-indications to tocolysis
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deirdre Judith Lyell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Deirdre J Lyell, MD</last_name>
    <phone>(650) 736-1191</phone>
    <email>dlyell@stanford.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anna Girsen, PhD</last_name>
    <phone>650-725-5720</phone>
    <email>agirsen@stanford.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deirdre J Lyell, MD</last_name>
      <phone>650-736-1191</phone>
      <email>dlyell@stanford.edu</email>
    </contact>
    <contact_backup>
      <last_name>Yair Blumenfeld, MD</last_name>
      <phone>(650) 269-4665</phone>
      <email>yairb@stanford.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Deirdre Judith Lyell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 28, 2016</lastchanged_date>
  <firstreceived_date>June 13, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Deirdre Judith Lyell</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obstetric Labor, Premature</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Nifedipine</mesh_term>
    <mesh_term>Indomethacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
